Erschienen in:
13.06.2019 | Original Article – Cancer Research
Aberrant expression of Sec61α in esophageal cancers
verfasst von:
Kai Bachmann, Maximillian Bockhorn, Oliver Mann, Florian Gebauer, Marco Blessmann, Jakob Robert Izbicki, Katharina Grupp
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Abstract
Introduction
The heterotrimeric Sec61α translocon complex is topological located in the membrane of the endoplasmic reticulum (ER) and allows protein transport and calcium across the membrane. Recently, aberrant expression of Sec proteins was linked to carcinogenesis and prognosis of patients.
Materials and methods
Here, we analysed the role of Sec61α in esophageal cancer, and we analysed Sec61α staining on a tissue microarray containing more than 600 esophageal cancer specimens by immunohistochemistry.
Results
Sec61α staining was always strong in benign esophagus, but was only found in 5% of interpretable esophageal adenocarcinomas (EACs) and 14.5% of squamous cell carcinomas (ESCCs). Reduced Sec61α staining was not strongly linked to tumor phenotype in both subgroups of esophageal cancers and was unrelated to clinical outcome of patients (EACs: p = 0.8051 and ESCCs: p = 0.2751).
Conclusions
Thus, Sec61α measurement has not an additional prognostic benefit for the patients.